本帖最后由 老马 于 2012-1-13 21:20 编辑
, A$ e/ K1 P' K9 y
# w* G! H. i9 b3 ^3 P5 P' m: h爱必妥和阿瓦斯丁的比较0 z, H, d( x. v' \7 r- A- w! i- j
1 X. _! e! V& r+ H4 v7 Q( z
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/, o! I1 ]& N/ D, C
9 M1 W& H& I3 l5 \) u) z
1 v9 d( M2 m6 n \ y4 shttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
+ v1 {0 I9 O: _2 N==================================================. I3 e* _% e( u x% ]
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
- ~: k8 m" J8 ?9 J2 ]3 NPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
6 E/ v: q+ ], C% |5 s4 K3 OResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.' Z9 A$ B4 j$ M i6 h
|